

Steven P Balk

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4572283/steven-p-balk-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

118
papers

10,263
citations

49
h-index

101
g-index

134
ext. papers

11,679
ext. citations

11.3
avg, IF

5.78
L-index

#	Paper	IF	Citations
118	Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. <i>New England Journal of Medicine</i> , 1995 , 332, 1393-8	59.2	1002
117	Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. <i>Cancer Research</i> , 2006 , 66, 2815-25	10.1	830
116	Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. <i>Cell</i> , 2009 , 138, 245-56	56.2	691
115	Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. <i>Nature</i> , 1998 , 391, 177-81	50.4	613
114	Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8- T cells. <i>Journal of Experimental Medicine</i> , 1997 , 186, 109-20	16.6	478
113	Biology of prostate-specific antigen. <i>Journal of Clinical Oncology</i> , 2003 , 21, 383-91	2.2	441
112	Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. <i>Immunity</i> , 2012 , 37, 574-87	32.3	348
111	Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. <i>Cancer Research</i> , 2011 , 71, 6503-13	10.1	326
110	Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. <i>Cancer Cell</i> , 2011 , 20, 457-71	24.3	314
109	Loss of IFN-gamma production by invariant NK T cells in advanced cancer. <i>Journal of Immunology</i> , 2001 , 167, 4046-50	5.3	305
108	AR, the cell cycle, and prostate cancer. <i>Nuclear Receptor Signaling</i> , 2008 , 6, e001	1	248
107	Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. <i>Cancer Research</i> , 2006 , 66, 7783-92	10.1	227
106	Actin-containing matrix associated with the plasma membrane of murine tumour and lymphoid cells. <i>Nature</i> , 1981 , 289, 139-44	50.4	181
105	Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. <i>Journal of Biological Chemistry</i> , 2002 , 277, 26321-6	5.4	176
104	Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3705-15	2.2	169
103	Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. <i>Journal of Clinical Investigation</i> , 2019 , 129, 192-208	15.9	157
102	Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 15969-74	11.5	154

101	Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. <i>American Journal of Pathology</i> , 1999 , 155, 1271-9	5.8	152
100	Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 1590-600	12.9	132
99	Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. <i>Clinical Cancer Research</i> , 2015 , 21, 1273-80	12.9	129
98	Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. <i>Cancer Research</i> , 2009 , 69, 6027-32	10.1	116
97	Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. <i>Nature</i> , 2016 , 533, 547-51	50.4	116
96	Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. <i>Endocrine-Related Cancer</i> , 2011 , 18, R175-82	5.7	112
95	AR and ER interaction with a p21-activated kinase (PAK6). <i>Molecular Endocrinology</i> , 2002 , 16, 85-99		111
94	SOX9 drives WNT pathway activation in prostate cancer. <i>Journal of Clinical Investigation</i> , 2016 , 126, 1745-58	15.8	106
93	Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. <i>Prostate</i> , 2005 , 63, 215-21	4.2	87
92	Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2017 , 23, 3510-3519	12.9	86
91	CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 8874-9	11.5	83
90	Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity. <i>Cell Reports</i> , 2014 , 9, 1618-1627	10.6	82
89	Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. <i>Cancer Discovery</i> , 2017 , 7, 750-765	24.4	77
88	Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop. <i>European Journal of Immunology</i> , 2008 , 38, 1756-66	6.1	77
87	Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. <i>Journal of Biological Chemistry</i> , 2012 , 287, 8571-83	5.4	76
86	ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. <i>Cancer Cell</i> , 2019 , 35, 401-413.e6	24.3	74
85	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. <i>European Urology</i> , 2018 , 73, 715-723	10.2	71
84	Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. <i>Journal of Biological Chemistry</i> , 2010 , 285, 14980-14989	5.4	71

83	Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells. <i>Molecular Endocrinology</i> , 2004 , 18, 2388-401		71
82	Clonal progression of prostate cancers from Gleason grade 3 to grade 4. <i>Cancer Research</i> , 2013 , 73, 1050-5	5.1	70
81	Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 2100-8	12.9	70
80	Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. <i>Clinical Cancer Research</i> , 2014 , 20, 4075-85	12.9	69
79	The altered expression of MiR-221/222 and MiR-23b/27b is associated with the development of human castration resistant prostate cancer. <i>Prostate</i> , 2012 , 72, 1093-103	4.2	65
78	Tumor susceptibility gene 101 protein represses androgen receptor transactivation and interacts with p300. <i>Cancer</i> , 1999 , 86, 689-96	6.4	64
77	PTEN-deficient tumors depend on AKT2 for maintenance and survival. <i>Cancer Discovery</i> , 2014 , 4, 942-55	24.4	62
76	Increased PAK6 expression in prostate cancer and identification of PAK6 associated proteins. <i>Prostate</i> , 2008 , 68, 1510-6	4.2	61
75	Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. <i>Clinical Cancer Research</i> , 2017 , 23, 6812-6822	12.9	58
74	Activation of beta-catenin signaling in prostate cancer by peptidyl-prolyl isomerase Pin1-mediated abrogation of the androgen receptor-beta-catenin interaction. <i>Molecular and Cellular Biology</i> , 2006 , 26, 929-39	4.8	57
73	Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. <i>Cancer Cell</i> , 2020 , 38, 279-296.e9	24.3	57
72	Neoadjuvant Enzalutamide Prior to Prostatectomy. <i>Clinical Cancer Research</i> , 2017 , 23, 2169-2176	12.9	50
71	The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer. <i>Chemico-Biological Interactions</i> , 2015 , 234, 332-8	5	49
70	Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with Galactosylceramide. <i>PLoS ONE</i> , 2010 , 5, e11311	3.7	49
69	The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells. <i>Journal of Urology</i> , 2015 , 193, 690-8	2.5	48
68	Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein. <i>Cell Reports</i> , 2016 , 17, 966-976	10.6	40
67	Activation of p21-activated kinase 6 by MAP kinase kinase 6 and p38 MAP kinase. <i>Journal of Biological Chemistry</i> , 2005 , 280, 3323-30	5.4	40
66	EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. <i>Nature Cancer</i> , 2021 , 2, 444-456	15.4	37

65	Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects. <i>Clinical Immunology</i> , 2011 , 140, 184-95	9	36
64	Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. <i>Cancer Research</i> , 2018 , 78, 4716-4730	10.1	33
63	Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. <i>Clinical Cancer Research</i> , 2018 , 24, 5458-5470	12.9	31
62	Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells. <i>Journal of Immunology</i> , 2008 , 180, 7287-93	5.3	31
61	Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4. <i>Clinical Cancer Research</i> , 2017 , 23, 3823-3833	12.9	30
60	Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells. <i>Journal of Biological Chemistry</i> , 2007 , 282, 32689-98	5.4	30
59	ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 3672-82	12.9	28
58	Intraepithelial lymphocytes and their recognition of non-classical MHC molecules. <i>International Reviews of Immunology</i> , 1994 , 11, 15-30	4.6	28
57	Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. <i>Nature Genetics</i> , 2020 , 52, 1011-1017	36.3	28
56	Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer. <i>Cancer Research</i> , 2020 , 80, 2094-2100	10.1	28
55	Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 426-439	12.9	27
54	Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4521-4521	2.2	26
53	Association of Tissue Abiraterone Levels and Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 4592-4601	12.9	25
52	Transcriptional mediators of treatment resistance in lethal prostate cancer. <i>Nature Medicine</i> , 2021 , 27, 426-433	50.5	25
51	Downregulation of Accelerates Progression to Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2018 , 78, 6354-6362	10.1	25
50	A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 935-945	12.9	22
49	Positive feedback loop mediated by protein phosphatase 1 α mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer. <i>Nucleic Acids Research</i> , 2017 , 45, 3738-3751	20.1	21
48	Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 320-329	12.9	19

47	Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases. <i>Science Signaling</i> , 2013 , 6, ra40	8.8	18
46	Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival. <i>Experimental Hematology</i> , 2008 , 36, 464-72	3.1	18
45	Evidence of T cell receptor beta-chain patterns in inflammatory and noninflammatory bowel disease states. <i>American Journal of Physiology - Renal Physiology</i> , 1999 , 276, G613-21	5.1	18
44	Taxane resistance in prostate cancer mediated by AR-independent GATA2 regulation of IGF2. <i>Cancer Cell</i> , 2015 , 27, 158-9	24.3	16
43	Targeting the androgen receptor and overcoming resistance in prostate cancer. <i>Current Opinion in Oncology</i> , 2019 , 31, 175-182	4.2	16
42	Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation. <i>Oncotarget</i> , 2016 , 7, 1754-64	3.3	15
41	Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	14
40	Androgen receptor epigenetics. <i>Translational Andrology and Urology</i> , 2013 , 2, 148-157	2.3	14
39	BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer. <i>Cancer Research</i> , 2018 , 78, 5203-5215	10.1	13
38	Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors. <i>Cell Chemical Biology</i> , 2021 , 28, 134-147.e14	8.2	13
37	MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation. <i>ELife</i> , 2020 , 9,	8.9	12
36	Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer. <i>Cancer Letters</i> , 2018 , 438, 97-104	9.9	10
35	Reprogramming to resist. <i>Science</i> , 2017 , 355, 29-30	33.3	9
34	Androgen Receptor Interaction with Mediator Complex Is Enhanced in Castration-Resistant Prostate Cancer by CDK7 Phosphorylation of MED1. <i>Cancer Discovery</i> , 2019 , 9, 1490-1492	24.4	9
33	Doxycycline regulated induction of AKT in murine prostate drives proliferation independently of p27 cyclin dependent kinase inhibitor downregulation. <i>PLoS ONE</i> , 2012 , 7, e41330	3.7	9
32	Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2017 , 1,	3.6	8
31	Loss of Wave1 gene defines a subtype of lethal prostate cancer. <i>Oncotarget</i> , 2015 , 6, 12383-91	3.3	8
30	Androgen receptor functions in prostate cancer development and progression. <i>Asian Journal of Andrology</i> , 2014 , 16, 561-4	2.8	8

29	Isolation and Functional Use of Human NKT Cells. <i>Current Protocols in Immunology</i> , 2017 , 119, 14.11.1-14.11.207		
28	Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy. <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 560-568	6.2	7
27	Calcium signaling: an underlying link between cardiac disease and carcinogenesis. <i>Cell and Bioscience</i> , 2018 , 8, 39	9.8	7
26	Mutation Profiling Indicates High Grade Prostatic Intraepithelial Neoplasia as Distant Precursors of Adjacent Invasive Prostatic Adenocarcinoma. <i>Prostate</i> , 2016 , 76, 1227-36	4.2	7
25	Initiation and Evolution of Early Onset Prostate Cancer. <i>Cancer Cell</i> , 2018 , 34, 874-876	24.3	7
24	A phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 274-274	2.2	6
23	A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. <i>Clinical Cancer Research</i> , 2021 , 27, 4836-4847	12.9	6
22	Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident. <i>American Journal of Hematology</i> , 2019 , 94, 62-73	7.1	6
21	ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer. <i>Cancer Research</i> , 2019 , 79, 5260-5271	10.1	5
20	MHC evolution. <i>Nature</i> , 1995 , 374, 505-6	50.4	5
19	Androgen receptor and MYC equilibration centralizes on developmental super-enhancer.. <i>Nature Communications</i> , 2021 , 12, 7308	17.4	4
18	Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. <i>Cell Reports</i> , 2021 , 36, 109665	10.6	4
17	Specific reversal of cytolytic T lymphocyte--target cell interaction. <i>Journal of Supramolecular Structure and Cellular Biochemistry</i> , 1981 , 16, 43-52		2
16	Neoadjuvant androgen pathway suppression prior to prostatectomy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4520-4520	2.2	2
15	Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	2
14	Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells. <i>Cancer Letters</i> , 2021 , 519, 172-184	9.9	2
13	A phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS2641-TPS2641	2.2	1
12	Ubiquitin Ligase MARCH5 Regulates Apoptosis through Mediation of Stress-Induced and NOXA-Dependent MCL1 Degradation		1

11	Association of SLCO transport genes with intraprostatic abiraterone (ABI) levels and pathologic outcomes in men with high-risk localized prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5013-5013	2.2	1
10	A Case of Prostate Cancer Harboring Androgen Receptor T878A Progesterone-Responsive Mutant Emerging After Abiraterone Acetate Treatment Responding to Darolutamide.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100091	3.6	1
9	Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 6001-6011	12.9	0
8	Circulating-free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 174-174	2.2	
7	In Vitro Generation of Highly-Purified Functional Invariant NKT Cells: A Strategy for Immunotherapy in Multiple Myeloma.. <i>Blood</i> , 2005 , 106, 5183-5183	2.2	
6	In Vitro Generation of Highly Purified Functional Invariant NKT Cells in Multiple Myeloma: A Strategy for Immunotherapy.. <i>Blood</i> , 2006 , 108, 5104-5104	2.2	
5	Measurement science of the androgen receptor splice variant-7 protein in primary and castration-resistant prostate cancer tissue.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 151-151	2.2	
4	A phase II study of nivolumab in patients with high-risk biochemically recurrent (BCR) prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS341-TPS341	2.2	
3	Association of serum (SR) and tissue (TX) abiraterone (ABI) levels with intraprostatic steroids and pathologic outcomes in men with high-risk localized prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5015-5015	2.2	
2	Fine tuning metabolism of biochemically active abiraterone metabolites to optimize anti-androgen therapy in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5016-5016	2.2	
1	Genomic mechanisms of resistance to neoadjuvant leuprolide plus abiraterone in locally advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 98-98	2.2	